{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-002173","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.016571+00:00","generated_at":"2026-05-16T11:26:38.235231+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Turn Therapeutics appoints Martin Dewhurst to its Board of Directors","bullets":["Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.","Over 30 years life sciences experience; former McKinsey senior partner and co-leader of global life sciences practice.","Received initial RSU grant with $100,000 fair value, vesting at one year or change of control.","Will chair compensation committee; eligible for annual $70,000 RSU grant after first anniversary of direct listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-002173","json":"https://secwatch.observer/filing/0001213900-26-002173.json","markdown":"https://secwatch.observer/filing/0001213900-26-002173.md","text":"https://secwatch.observer/filing/0001213900-26-002173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/0001213900-26-002173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/ea0272109-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:26:38.235231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}